Renal Lesions Associated with IgM-Secreting Monoclonal Proliferations

Audard, Vincent; Georges, Benoît; Vanhille, Philippe; Toly, Cécile; Deroure, Benjamin; Fakhouri, Fádi; Cuvelier, R; Belenfant, Xavier; Surin, Brigitte; Aucouturier, Pièrre; Mougenot, B; Ronco, Pierre

doi:10.2215/cjn.01600408

Cited by 93 publications

(85 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These include myeloma kidney (cast nephropathy), AL amyloidosis, and light-chain deposition disease (13). The spectrum of renal lesions associated with monoclonal gammopathy is extensive (14) and depends on the physiochemical properties of the Ig produced. Of the 2603 native renal biopsies done at the Mayo Clinic from 2001 through 2006, 239 showed AL amyloidosis (9.16%), 30 showed myeloma kidney (1.3%), 48 showed light-chain deposition disease (1.8%), and only one showed heavy-chain deposition disease.…”

Section: Discussionmentioning

confidence: 99%

Membranoproliferative Glomerulonephritis Secondary to Monoclonal Gammopathy

Sethi

Zand

Leung

et al. 2010

Clinical Journal of the American Society of Nephrology

167

124

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Membranoproliferative Glomerulonephritis Secondary to Monoclonal Gammopathy

Sethi

Zand

Leung

et al. 2010

Clinical Journal of the American Society of Nephrology

167

124

View full text Add to dashboard Cite

“…Thrombotic microangiopathy, typically limited to the kidney, can result from Ig-induced endothelial injury as well as systemic chemotherapy or stem cell transplantation used to treat myeloma (18). Monoclonal IgM, which is a much larger molecule than IgG, can produce hyperviscosityassociated renal impairment and additionally form deposits that occlude glomerular capillaries (19). Monoclonal IgA can result in IgA nephopathy or Henoch-Schonlein purpura, although this result is uncommon (20).…”

Section: Mechanisms Of Myeloma and Plasma Cell-associated Kidney Injurymentioning

confidence: 99%

Kidney Disease and Multiple Myeloma

Heher

Rennke

Laubach

et al. 2013

Clinical Journal of the American Society of Nephrology

145

122

View full text Add to dashboard Cite

SummaryKidney injury is a common complication of multiple myeloma and other plasma cell dyscrasias, and it is associated with increased mortality. Multiple pathogenic mechanisms can contribute to kidney injury in the patient with myeloma, some of which are the result of nephrotoxic monoclonal Ig and some of which are independent of paraprotein deposition. The pathogenic mechanisms that underlie paraprotein-related kidney disease are increasingly well understood. A novel assay allowing the quantification of free light chains in the serum has aided the diagnosis of new onset disease and allowed for the earlier detection of relapse. Novel myeloma agents have shown considerable promise in reversing renal failure in some patients and improving outcomes. Stem cell transplantation remains a mainstay of management for younger patients with myeloma who are suitable candidates for intensive therapy, whereas the role of new drugs, plasma exchange, and kidney transplantation continues to evolve.

show abstract

“…The incidence of renal complications of malignant IgMsecreting proliferation has decreased, mostly because of improved treatment of WM, the major cause of those nephropathies. Audard et al (62), who recently revisited the disease spectrum, showed that GN with intracapillary thrombi of IgM, originally described by Morel-Maroger et al as Waldenström macroglobulinemic glomerulonephritis (55), was not specific for WM and suggested that the term intracapillary monoclonal deposits disease may be more appropriate in this context.…”

Section: Hematologic Malignancy-induced Paraneoplastic Glomerulopathimentioning

confidence: 99%

Onco-Nephrology

Cambier

Ronco

2012

Clinical Journal of the American Society of Nephrology

Self Cite

View full text Add to dashboard Cite

SummaryGlomerular diseases occurring in the course of malignancies remain rare. Diverse glomerular lesions can be observed in a variety of neoplasms and involve different pathophysiologic links between the glomerulopathy and the cancer. The pathophysiology of solid tumor-associated glomerulopathies remains obscure, whereas in hematologic malignancy-induced paraneoplastic glomerulopathies, a molecular link can usually be demonstrated. The aim of this review is to provide an update on glomerular diseases associated with carcinoma and hematologic malignancies, covering epidemiology, pathophysiology, clinical presentation, and therapy. Special emphasis will be placed on the potential usefulness of novel biomarkers, such as antiphospholipase A2 receptor antibodies, for the diagnosis of membranous nephropathy, and on new associations and recent entities, including (proliferative) GN with nonorganized monoclonal immunoglobulin deposits and myeloproliferative neoplasmrelated glomerulopathy.

show abstract

Renal Lesions Associated with IgM-Secreting Monoclonal Proliferations

Cited by 93 publications

References 34 publications

Membranoproliferative Glomerulonephritis Secondary to Monoclonal Gammopathy

Membranoproliferative Glomerulonephritis Secondary to Monoclonal Gammopathy

Kidney Disease and Multiple Myeloma

Onco-Nephrology

Contact Info

Product

Resources

About